COMMUNIQUÉS West-GlobeNewswire

Communiqué de presse : MenQuadfi de Sanofi approuvé dans l’UE pour une utilisation chez les nourrissons dès l’âge de six semaines contre les infections invasives à méningocoques
04/08/2026
MenQuadfi de Sanofi approuvé dans l’UE pour une utilisation chez les nourrissons dès l’âge de six semaines contre les infections invasives à méningocoques Paris, le 4 août 2026. Sanofi a annoncé aujourd’hui que la [...]
Rapid Nutrition Joins Global Conversation on the Future of AI-Driven HealthTech
04/08/2026
Growing recognition across leading international business media highlights increasing interest in the convergence of artificial intelligence, personalized wellness and digital health. LONDON, Aug. 03, 2026 (GLOBE [...]
Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
04/08/2026
Phase 3 trial designed to demonstrate superiority of bexobrutideg versus pirtobrutinib in patients with relapsed/refractory CLL/SLL previously treated with a covalent BTK inhibitor BRISBANE, Calif., Aug. 04, 2026 (GLOBE [...]
Press Release: Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease
04/08/2026
Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal disease Paris, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an [...]
InnoCare Announces Orelabrutinib in Combination with Mesutoclax Granted Breakthrough Therapy Designation in China
04/08/2026
BEIJING, Aug. 03, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that orelabrutinib [...]
Dyadic to Report Q2 2026 Financial Results and Host Conference Call on Wednesday August 12, 2026
03/08/2026
JUPITER, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the [...]
DentaBiome Details Oral Postbiotic Formula and Sourcing Amid 2026 Dental Caries Research
03/08/2026
Berry Frost chewable formula pairs Lactobacillus postbiotic strains, xylitol, cranberry extract and purple carrot powder in a GMP-certified US facility. Tallmadge, OH, Aug. 03, 2026 (GLOBE NEWSWIRE) -- These statements [...]
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
03/08/2026
Delivered ~ 15% WW revenue growth and ~ 178% increase in adjusted EBITDA ~ 19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of [...]
Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
03/08/2026
CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral [...]
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/08/2026
BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on August 1, 2026, the Compensation [...]
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/08/2026
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib [...]
Direct Meds Expands DirectMax Patient Access and Prescription Fulfillment Information
03/08/2026
Direct Meds has expanded the patient information available for DirectMax, including its online clinical-review process, compounded-medication status, licensed-pharmacy fulfillment structure, recurring-plan terms and [...]
CapsoVision® Announces International Launch of AI Highlights
03/08/2026
AI-assisted review feature designed to support physician review of small bowel capsule endoscopy studies using the CapsoCam Plus® system SARATOGA, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV [...]
Dianthus Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
04/08/2026
NEW YORK and WALTHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Seer to Participate in the Canaccord Genuity 46th Annual Growth Conference
03/08/2026
REDWOOD CITY, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the [...]
AEON Biopharma Regains Compliance with NYSE American Continued Listing Standards
03/08/2026
ALISO VIEJO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX ® (onabotulinumtoxinA) [...]
Vireo Growth to Report Second Quarter 2026 Financial Results on August 11, 2026
03/08/2026
MINNEAPOLIS, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that the Company will host a conference call on Tuesday, August 11, 2026, at 8:00 a [...]
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
03/08/2026
Announced Vertex Agreement to Acquire Crinetics for Total Equity Value of Approximately $10.0 Billion, or Approximately $8.8B Net of Estimated Cash Acquired PALSONIFY® (Paltusotine) Net Product Revenue of $24.0 Million [...]
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03/08/2026
SAN DIEGO, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)- [...]

Pages